Among these recent advances, Sha et al. and Ennishi et al. have defined a clinically and biologically distinct high-risk subgroup within GCB-DLBCL using, respectively, a Burkitt lymphoma-like or MYC/BCL2-DH-founded gene expression signature [25–27]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.